NeoGenomics expands Indica Labs partnership for precision oncology

• NeoGenomics (NEO) expanded its partnership with Indica Labs to scale AI-powered digital pathology, aiming to improve diagnostic workflows and prepare for emerging cancer biomarker applications.
• The company selected Indica Labs’ cloud-based HALO AP platform to integrate third-party and internally developed AI tools while limiting integration costs and capital investment.
• The expanded infrastructure is expected to support AI-based biomarker testing, future AI development and clinical trial collaborations as oncology diagnostics evolve.

Recommended For You

Create Your Free Account to Keep Reading

Get the confidence to navigate an uncertain market with free breaking news and stock alerts.